Gara Jalqabaatti › Lupus Nephritis
Qorannoo klinikaalii Lupus Nephritis Ameerikaa Keessatti hirmaatuu
Qorannoo 33 Lupus Nephritis f bakka adda addaa Ameerikaa Keessatti hirmaatuu jiru.
Magaalota qorannoo baay'ee qaban
- New York City, NYQorannoo 10
- Chicago, ILQorannoo 9
- Atlanta, GAQorannoo 9
- Houston, TXQorannoo 8
- Durham, NCQorannoo 8
- Boston, MAQorannoo 7
- Philadelphia, PAQorannoo 7
- San Francisco, CAQorannoo 7
- Aurora, COQorannoo 5
- Miami, FLQorannoo 5
- St. Louis, MOQorannoo 5
- Cleveland, OHQorannoo 4
- Los Angeles, CAQorannoo 4
- Dallas, TXQorannoo 4
- Syracuse, NYQorannoo 4
- Charleston, SCQorannoo 4
- Charlotte, NCQorannoo 4
- Washington, DCQorannoo 3
- New Orleans, LAQorannoo 3
- Johns Creek, GAQorannoo 3
- Worcester, MAQorannoo 3
- Santa Monica, CAQorannoo 3
- Columbus, OHQorannoo 3
- Jacksonville, FLQorannoo 3
- Baltimore, MDQorannoo 3
- Gainesville, FLQorannoo 3
Naannoon
- ArizonaQorannoo 3
- CaliforniaQorannoo 15
- ColoradoQorannoo 7
- FloridaQorannoo 11
- GeorgiaQorannoo 11
- IllinoisQorannoo 9
- KansasQorannoo 3
- LouisianaQorannoo 5
- MarylandQorannoo 5
- MassachusettsQorannoo 8
- MichiganQorannoo 3
- MinnesotaQorannoo 3
- MissouriQorannoo 6
- New JerseyQorannoo 5
- New YorkQorannoo 16
- North CarolinaQorannoo 11
- OhioQorannoo 7
- PennsylvaniaQorannoo 7
- South CarolinaQorannoo 5
- TennesseeQorannoo 4
- TexasQorannoo 12
Qorannoo yeroo dhihootti haaromfaman
Takkalaa qorannoo (Ingiliffa)
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 hanga 100 · Saalaa hunda · Haaromfame 01-Onk-2026 · NCT05268289A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 16 fi ol · Saalaa hunda · Haaromfame 01-Onk-2026 · NCT06419205Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 hanga 100 · Saalaa hunda · Haaromfame 28-Ful-2026 · NCT06711887CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 10 hanga 29 · Saalaa hunda · Haaromfame 24-Ful-2026 · NCT06839976A Phase IIa Study of ICG318 CAR-T in Refractory Systemic Lupus Erythematosus With or Without Lupus Nephritis
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 16 hanga 70 · Saalaa hunda · Haaromfame 17-Ful-2026 · NCT07328581Study of Systemic Lupus Erythematosus
Namoota walitti qabaa jiraQorannoo ilaalaaHojjettoota fayyaa simatamoo
Umuriin 3 hanga 120 · Saalaa hunda · Haaromfame 16-Ful-2026 · NCT00001372VIBRANT: VIB4920 for Active Lupus Nephritis
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 16-Ful-2026 · NCT05201469Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 hanga 60 · Saalaa hunda · Haaromfame 14-Ful-2026 · NCT06975787The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 8 hanga 20 · Saalaa hunda · Haaromfame 14-Ful-2026 · NCT05538208A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 12 hanga 70 · Saalaa hunda · Haaromfame 14-Ful-2026 · NCT07570862A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 hanga 70 · Saalaa hunda · Haaromfame 10-Ful-2026 · NCT06897930A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 hanga 74 · Saalaa hunda · Haaromfame 10-Ful-2026 · NCT07085104A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 5 hanga 17 · Saalaa hunda · Haaromfame 03-Ful-2026 · NCT05039619A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 hanga 70 · Saalaa hunda · Haaromfame 28-Hag-2026 · NCT06925542RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 hanga 65 · Saalaa hunda · Haaromfame 26-Hag-2026 · NCT06121297Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN)
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 12 hanga 65 · Saalaa hunda · Haaromfame 24-Hag-2026 · NCT07053800PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis
Namoota walitti qabaa jiraSadarkaa 4
Umuriin 18 hanga 75 · Saalaa hunda · Haaromfame 03-Hag-2026 · NCT07611214A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 hanga 75 · Saalaa hunda · Haaromfame 30-Ado-2026 · NCT07201129Wellness & Workforce Solution for Lupus/Lupus Nephritis
Namoota walitti qabaa jiraHojjettoota fayyaa simatamoo
Umuriin 18 fi ol · Dubartoota · Haaromfame 24-Ado-2026 · NCT06217107A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 14-Ado-2026 · NCT07115745Study to Assess Real-world Effectiveness of Belimumab for Treatment of Adults With LN
Namoota walitti qabaa jiraQorannoo ilaalaa
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 02-Ado-2026 · NCT06527872US Zamto-cel Autoimmune Diseases
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 11-Wax-2026 · NCT06708845A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 hanga 75 · Saalaa hunda · Haaromfame 04-Wax-2026 · NCT06557265Dapagliflozin in Active Lupus Nephritis
Namoota walitti qabaa jiraSadarkaa 4
Umuriin 18 hanga 70 · Saalaa hunda · Haaromfame 26-Cam-2026 · NCT07323524A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 12 hanga 70 · Saalaa hunda · Haaromfame 22-Cam-2026 · NCT06308978Kanneen ClinicalTrials.gov irraa argaman, daataa 05-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.